American CryoStem to Present at National Investment Banking Association's 126th Investment Conference
04 Giugno 2013 - 2:30PM
American CryoStem Corporation (OTCQB:CRYO), a
leading strategic developer, marketer and global licensor of
patented adipose tissue-based cellular technologies for the
Regenerative and Personalized Medicine industries, today announced
that the Company has been invited to present at the National
Investment Banking Association's (NIBA) 126th Investment Conference
to be held in New York City, June 17-19, 2013.
John Arnone, CEO commented, "Now that our cutting-edge products
are ready for commercialization after years of research and
development, presenting at the NIBA Investment Conference will
provide American CryoStem the platform to display its proprietary
adipose derived stem cell technologies. This will be the Company's
first public financial presentation, we look forward to developing
strong financial alliances to continue the growth of our business
model and expand our sales and marketing efforts as the
Regenerative Medicine Industry takes hold globally."
NIBA is a national not-for-profit trade association of regional
and independent brokerages, investment banking firms, institutional
investors and related capital market service providers. Since its
inception, NIBA member firms have successfully completed over 1000
equity offerings totaling approximately $10 billion in new capital
for America's finest emerging growth companies. The member firms of
NIBA represent over 8800 registered representatives with an
estimated $78 billion in assets under management, and are
responsible for 90% of all Initial Public Offerings under $20
million.
NIBA conferences provide a venue for invited companies to share
meaningful insight into their business operations, short and
long-term growth strategies and industry vision, and give its
members the opportunity to exchange ideas and information, evaluate
presentations made by public and private companies seeking capital
or exposure, collectively voice their positions on issues impacting
the securities industry, and enhance their knowledge and expertise
through ongoing education programs designed to enable them to
remain competitive in today's financial market.
EVENT AT A GLANCE
WHO: |
John Arnone – Chairman and CEO |
|
Anthony Dudzinski – COO |
|
|
WHEN: |
June 17 – 19, 2013 |
|
|
WHERE: |
New York Marriott Downtown |
|
85 West Street at Albany Street |
|
New York, New York |
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized
Medicine, American CryoStem is a developer, marketer and global
licensor of patented adipose tissue-based cellular technologies and
related proprietary services with a focus on clinical processing,
commercial bio-banking and application development for adipose
(fat) tissue and autologous adipose-derived regenerative cells
(ADRCs). The Company maintains a strategic portfolio of
intellectual property and patent applications that form its Adipose
Tissue Processing Platform, which supports and promotes a growing
pipeline of biologic products and processes, clinical services and
international licensing opportunities. Through its ACS
Laboratories division, the Company operates an FDA registered, cGMP
compliant human tissue processing, cryo-storage, cell culture and
differentiation media development facility in Mount Laurel, New
Jersey. For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
CONTACT: Hanover|Elite
Dodi Handy or Kathy Addison
407-585-1080 or via email at CRYO@hanoverelite.com
Grafico Azioni American Cryostem (CE) (USOTC:CRYO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni American Cryostem (CE) (USOTC:CRYO)
Storico
Da Giu 2023 a Giu 2024